A Bioequivalence Study of the Fixed Dose Combination Dapagliflozin/Metformin Tablet (5 mg/850 mg) Relative to a 5 mg Dapagliflozin Tablet and an 850 mg Metformin (Glucophage (Rm) Marketed in Canada by Sanofi-Aventis) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States
Phase of Trial: Phase I
Latest Information Update: 06 Aug 2015
At a glance
- Drugs Dapagliflozin (Primary) ; Dapagliflozin/metformin (Primary) ; Metformin (Primary)
- Indications Diabetes mellitus
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Apr 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 08 Mar 2013 Planned End Date changed from 1 Jun 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.